Project Grant R41GM145048
- This Project Grant award from the National Institutes of Health's National Human Genome Research Institute provided $768,678 to Molecular Assemblies, Inc. to develop a fully enzymatic oligonucleotide synthesis cycle using engineered template-independent polymerases and a novel phosphate dNTP blocking group. The award supports the goals of the Human Genome Research program (CFDA 93.172) to accelerate genome research and its application to human health. Specifically, the awardee will engineer...
- This Project Grant award from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) provides $452,375 to The Trustees of Columbia University in the City of New York to develop a platform for rapid and efficient generation of multi-site sequence variants using template-guided gene synthesis. The project aims to advance this synthesis approach by optimizing predictive algorithms, experimental protocols, and robotic automation to produce kilobase-sized DNA constructs up...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $394,857 to the University of Nebraska to develop a system to protect and concentrate large DNA molecules for genome analysis. The project aims to: Develop an inverted insert to protect DNA during cell lysis. Develop a roadblock to concentrate chromosomal DNA. The goal is to create a method to protect and concentrate large DNA molecules...
- Triton Systems, Inc. received a $249,712 Project Grant award from the Department of Energy Office of Science on February 22, 2021 to develop a fast, scalable, automated, one-pot process for assembly of DNA oligonucleotides into large gene sequences. The work will be performed in Chelmsford, Massachusetts through February 21, 2022. The award is being made under the Office of Science Financial Assistance Program (CFDA #81.049), which supports basic research to deliver scientific discoveries and...
- This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) is providing $275,000 to Dinya DNA Inc. to support the commercial development of a novel DNA synthesis technology. The key products or services being delivered include: Developing new methods to ensure higher fidelity DNA precursors, which are the building blocks for DNA synthesis Reducing synthesis costs by streamlining the DNA synthesis reactions...
- This Project Grant award of $500,000.00 from the National Science Foundation's Computer and Information Science and Engineering (CISE) program, with a performance period from July 1, 2025 to June 30, 2028, supports research to develop new methods for improving the accuracy and efficiency of genome assembly. The project aims to address key computational challenges in assembling complete genomic sequences from fragmented DNA data, which is critical for enabling scientific discoveries and practical...
- The National Institute of General Medical Sciences (NIGMS) awarded a $306,872 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Chesapeake Genomic Systems, LLC, a biotechnology research and development company located in Halethorpe, Maryland. The grant, awarded on September 5, 2025, with a completion date of August 31, 2026, supports the development of a bacteria-free technology that generates synthetic circular supercoiled DNA (scsDNA). This technology...
- The National Human Genome Research Institute (NHGRI) awarded a $291,232 Project Grant to Micropure Genomics Inc. on September 17, 2025 under the Human Genome Research Federal Grant Program (CFDA 93.172). The project aims to develop an automated, bead-less, and gel-less microfluidic size selection approach to simplify workflows, reduce costs, and enhance the performance of long-read DNA sequencing technologies such as PacBio and Oxford Nanopore. The proposed innovation, called mPREP, leverages...
- This SBIR Phase I project, funded by the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop hardware that enables the rapid and cost-effective synthesis of DNA-encoded libraries (DELs). The $294,932 award, granted to Femtofluidics Incorporated, will be used to build a device that can perform combinatorial chemistry on nanoliter to picoliter volume droplets using an electronic substrate, rather than traditional liquid-handling...
- The National Human Genome Research Institute (NHGRI), under the Human Genome Research Federal Grant Program (CFDA 93.172), awarded a $384,418 Project Grant to Xgenomes Corp. on September 25, 2024 to develop a revolutionary DNA sequencing platform. The project aims to create a super-resolution single-molecule sequencing technology that can read short sequence "words" rather than individual nucleotides, enabling one or more orders of magnitude improvements in accuracy and cost over...
HETERODUPLEX THERMOSTABLE LIGATION ASSEMBLY: A NEW PLATFORM TO RAPIDLY GENERATE LARGE DNA MOLECULES - IN VITRO ASSEMBLY OF DNA FRAGMENTS >20 KB HAS RECENTLY IDENTIFIED AS A CRITICAL TECHNICAL CHALLENGE FOR WRITING SYNTHETIC GENOMES. MEETING THIS CHALLENGE WILL INCREASE THE EFFICIENCY OF GENOME WRITING PROJECTS THAT DEPEND ON LARGE SYNTHETIC DNAS, WHICH ARE ITERATIVELY RECOMBINED TO REPLACE CHROMOSOME REGIONS IN A STEP-WISE MANNER TO PARTIALLY OR COMPLETELY RE-WRITE BACTERIAL OR YEAST CHROMOSOMES. THE LONG-TERM GOAL OF THIS PROJECT IS TO DEVELOP AN EFFICIENT, LOW-COST STRATEGY TO GENERATE COMPLETELY SYNTHETIC LARGE DNAS, FROM >50 KB UP TO 1 MBP, WITHOUT HOMOLOGOUS RECOMBINATION IN YEAST OR BACTERIA. THE OBJECTIVE OF THE WORK PROPOSED HERE IS TO OPTIMIZE THE PARAMETERS OF THIS NOVEL APPROACH WE TERM HETERODUPLEX THERMOSTABLE LIGASE ASSEMBLY (HTLA) TO GENERATE LARGE DNAS COMPLETELY IN VITRO. THE RATIONALE FOR THIS WORK IS THAT SUCCESSFUL COMPLETION WILL PROVIDE PROOF-OF- CONCEPT THAT HETERODUPLEX CLONING CAN BE USED TO RAPIDLY GENERATE LARGE DNAS IN A LOW-COST, COMMERCIALIZABLE MANNER. TO ACCOMPLISH THESE GOALS WITHIN THE BUDGET, PCR-GENERATED BACTERIOPHAGE LAMBDA GENOME FRAGMENTS WILL BE USED AS A PARADIGM FOR DE NOVO SYNTHESIZED DNAS. TWO HTLA STRATEGIES TO GENERATE LARGE DNAS WILL BE SYSTEMATICALLY EXPLORED BY ACHIEVING THE GOALS OF THREE RELATED BUT INDEPENDENT SPECIFIC AIMS: 1) TO DETERMINE OPTIMAL HTLA CONDITIONS TO GENERATE ~2 KB FRAGMENTS WITH LIGATION-READY STICKY ENDS FOR ASSEMBLY OF A LARGE DNA CONSTRUCT. ONE-CYCLE HTLA REACTION CONDITIONS TO JOIN 1 KB LAMBDA GENOME PARTS TO GENERATE ~2 KB STICKY END BLOCKS (SEBS) WILL BE SYSTEMATICALLY VARIED TO MAXIMIZE YIELD. DNA PART OVERLAP LENGTH WILL ALSO BE OPTIMIZED. STICKY END LENGTH ON SEBS WILL THEN BE VARIED TO ACHIEVE OPTIMAL LIGATION WITH T4 OR 9N DNA LIGASE. SEBS WILL BE LIGATED IN INCREASING NUMBERS TO DETERMINE THE PRACTICAL LIMIT OF FINAL PRODUCT LENGTH. SEQUENCE FIDELITY OF ASSEMBLED SEQUENCES WILL BE DETERMINED; 2) TO DETERMINE THE MAXIMUM NUMBER OF ~1 KB HETERODUPLEX DNA MOLECULES THAT CAN BE REPRODUCIBLY JOINED IN A ONE-POT, ONE-STEP METHOD WITH HIGH SEQUENCE FIDELITY BY HTLA AND CYCLIC HETERODUPLEX THERMOSTABLE LIGATION ASSEMBLY (CHTLA). ONE KB LAMBDA GENOME PARTS IN INCREASING NUMBERS WILL BE JOINED USING HTLA TO DETERMINE THE UPPER SIZE LIMIT FOR SEB GENERATION WITH A YIELD SUFFICIENT FOR SUBSEQUENT STEPS. THE EFFECT OF DNA PART OVERLAP LENGTH (100-500) ON REACTION EFFICIENCY WILL BE DETERMINED. 10- CYCLE CHTLA REACTIONS WILL ALSO BE PERFORMED WITH INCREASING NUMBERS OF 1 KB LAMBDA GENOME PARTS TO PROBE THE UPPER LIMIT ON FINAL PRODUCT LENGTH THAT CAN BE GENERATED BY CHTLA. SEQUENCE FIDELITY WILL BE DETERMINED; 3) TO USE OPTIMIZED HETERODUPLEX CLONING STRATEGIES IDENTIFIED IN AIMS 1 AND/OR 2 TO SEAMLESSLY GENERATE A COMPLETE LAMBDA PHAGE GENOME THAT CAN BE PACKAGED INTO INFECTIOUS PARTICLES. USING OPTIMIZED CONDITIONS DETERMINED IN AIM 1 AND 2, A COMPLETELY ASSEMBLED LAMBDA GENOME WILL BE GENERATED, PACKAGED, AND USED TO INFECT E. COLI. SUCCESSFUL COMPLETION OF THIS PHASE 1 PROJECT WILL DEMONSTRATE THE UTILITY OF HTLA AND/OR CHTLA TO BUILD A FUNCTIONAL ~50 KB VIRAL GENOME IN VITRO. IN PHASE 2, WE WILL EXTEND THE UTILITY OF HETERODUPLEX CLONING TO GENERATE DNAS 100 KB TO >1 MBP IN LENGTH TO SERVICE THE $1.62B GENOME ENGINEERING AND EDITING MARKET (CAGR, 24.4%).
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 5/8/24 | ||
| Not listed | $256.6k | 9/23/21 | ||
| Not listed | $256.6k | 9/23/21 |